Published on
04:09 GMT
5 Accelerated Approvals Gone Wrong
When Pfizer pulled its sickle cell disease therapy Oxbryta from the worldwide market last month, it became part of a growing trend: drugs approved under the FDA’s accelerated approval pathway that have later disappointed, sometimes being withdrawn from the …
Source:
BioSpace
-
Label Pending
